Results 241 to 250 of about 472,601 (312)

[Mitochondrial diseases].

Pathologica, 1999
D'AMATI, Giulia, CASALI, Carlo, GIORDANO, Carla   +2 more
openaire   +2 more sources

Liquiritin Exerts a Dual Effect on BMSCs Osteogenic Differentiation and Fracture Healing by Activating the ERK/JNK Pathway and Providing Antioxidant Protection

Advanced Therapeutics, EarlyView.
Liquiritin enhances the osteogenic differentiation of BMSCs and promotes fracture healing through the activation of the ERK/JNK signaling pathway and by exerting antioxidant protective effects. Abstract Liquiritin, a flavonoid from Glycyrrhiza uralensis L., has diverse pharmacological properties, but its impact on fracture healing is unexplored.
Haijun Mao, Jing Liu, Juan Feng, Yalikun Yusufu, Lei Yang, Qing Jiang, Minghui Sun   +6 more
wiley   +1 more source

Role of Comprehensive Renal Genetic Testing in Diagnosing a <i>RMND-1</i> Mitochondrial Disease in Two Adult Cases Exhibiting Variable Disease Phenotypes. [PDF]

Clin Case Rep
Stein Q, Mascarenhas R, Punj S, Westemeyer M, Hendricks E, Pitman T, Hager M, Al Haj Baddar N, Connors K, Bacher A, Larson R, Zec L, Stoddard J.   +12 more
europepmc   +1 more source

Automated Transcranial Photobiomodulation in Healthy Rats: Effects on Working Memory and Brain Markers

Advanced Therapeutics, EarlyView.
Transcranial photobiomodulation (PBM) enhances spatial working memory in healthy rats under both continuous and alternating stimulation protocols. At the neural level, PBM modulates cytochrome c oxidase activity, increases prefrontal and hippocampal synaptic markers, and induces region‐specific c‐Fos expression. These effects suggest improved cognitive
Candela Zorzo, Lucía Rodríguez‐Fernández, Emily Gabriela Castillo‐Escalona, Juan A. Martínez, Laura Mañas, Natalia Arias, Jorge L. Arias   +6 more
wiley   +1 more source

Unilateral Hearing Loss and Auditory Asymmetry in Mitochondrial Disease: A Scoping Review. [PDF]

J Clin Med
Manuelli M, Migliorelli A, Bianchini C, Stomeo F, Pelucchi S, Genovese E, Monzani D, Palma S, Ciorba A.   +8 more
europepmc   +1 more source

Rewiring Neuroimmunity: Nanoplatform Innovations for CNS Disease Therapy

Advanced Therapeutics, EarlyView.
This review explores emerging nanoplatform strategies designed to modulate neuroimmune responses for treating central nervous system (CNS) disorders. It examines structural and microenvironmental barriers, advances in multifunctional and targeted nanotechnologies, and highlights clinical progress and translational challenges, offering insights into the
Muhammad Usman Akbar, Weiwei Guo, Xin Shen, Yimeng Fang, Yilin Liu, Peng‐Yuan Wang, Roey Elnathan, Yaping Chen   +7 more
wiley   +1 more source

Prenatal and progressive coenzyme Q₁₀ administration to mitigate muscle dysfunction in mitochondrial disease. [PDF]

J Cachexia Sarcopenia Muscle
Hernández-Camacho JD, Vicente-García C, Ardila-García L, Padilla-Campos A, López-Lluch G, Santos-Ocaña C, Zammit PS, Carvajal JJ, Navas P, Fernández-Ayala DJM.   +9 more
europepmc   +1 more source

Understanding miR‐200c: an Important Player in Resistance to Cancer Treatment

Advanced Therapeutics, EarlyView.
How can one microRNA alter cancer's response to therapy? miR‐200c plays a central role in therapeutic resistance by modulating epithelial‐mesenchymal transition, apoptosis, cancer stemness features, and drug efflux. This review outlines the context‐dependent functions of miR‐200c in various cancers and highlights its potential as both a biomarker and a
Fatma Sanli, Omer Faruk Karatas
wiley   +1 more source

Interpreting the clinical significance of multiple large-scale mitochondrial DNA deletions (MLSMD) in skeletal muscle tissue in the diagnostic evaluation of primary mitochondrial disease. [PDF]

Front Pharmacol
Wang J, Peterson JT, Santos JDD, Chan AJS, Diaz-Miranda MA, Rahaman I, Flickinger J, Goldstein A, Bogush E, McCormick EM, Muraresku CC, Anderson VE, Dulik MC, Wallace DC, Xiao R, Falk MJ, Viaene AN, Zolkipli-Cunningham Z.   +17 more
europepmc   +1 more source

SMYD3 Promotes Immune Evasion in Clear Cell Renal Cell Carcinoma via SREBP1‐Mediated Transactivation of CD47

Advanced Science, EarlyView.
Cancer cell‐intrinsic SMYD3 orchestrates an immunosuppressive microenvironment and impairs the response to PD‐1 blockade by reprogramming immune cells landscape in the tumor microenvironment of clear cell renal cell carcinoma (ccRCC). The immunomodulatory function of SMYD3 is mediated via the SREBP1/CD47 pathway.
Zhengfang Liu, Xiumei Zhao, Maolin Zang, Huiyang Yuan, Xin Qin, Xiaofeng Li, Shuo Zhao, Ruirong Tan, Keqiang Yan, Li Liu, Yidong Fan, Ning Zhang, Benkang Shi, Bo Han, Shouzhen Chen   +14 more
wiley   +1 more source